{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:38:14Z","timestamp":1791279494843,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2013-2923"],"award-info":[{"award-number":["2013-2923"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006133","name":"Anders Jahres Fond til Vitenskapens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["39562"],"award-info":[{"award-number":["39562"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["217780"],"award-info":[{"award-number":["217780"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimerfondet, Civitan"},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["237250"],"award-info":[{"award-number":["237250"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["237250"],"award-info":[{"award-number":["237250"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alzheimer\u2019s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to late-onset AD and other neurodegenerative disorders. TREM2, a microglial receptor, is involved in innate immunity. A cleaved fragment, soluble TREM2 (sTREM2), is present in the cerebrospinal fluid (CSF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed and used a novel enzyme-linked immunosorbent assay to investigate the potential value of CSF sTREM2 as an AD biomarker in two independent cohorts: an AD\/mild cognitive impairment (MCI)\/control cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009100) and an AD\/control cohort (<jats:italic>n<\/jats:italic>\u2009=\u200950).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found no significant difference in sTREM2 levels between groups of controls and patients with AD or MCI. However, among all controls there was a positive correlation between sTREM2 and age (Spearman rho\u2009=\u20090.50; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; <jats:italic>n<\/jats:italic>\u2009=\u200975). In the AD\/MCI\/control cohort, CSF sTREM2 correlated positively with total Tau (T-tau) (Spearman rho 0.57; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; <jats:italic>n<\/jats:italic>\u2009=\u200950), phosphorylated Tau (P-tau) (Spearman rho 0.63; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; <jats:italic>n<\/jats:italic>\u2009=\u200950) and amyloid-\u03b21\u201342 (A\u03b242) (Spearman rho 0.35; <jats:italic>p<\/jats:italic>\u2009=\u20090.01; <jats:italic>n<\/jats:italic>\u2009=\u200950) in control subjects. Among controls with a CSF A\u03b242 above a cut-off value (700\u00a0pg\/ml) in this cohort, the positive correlation between sTREM2 and A\u03b242 was stronger (Spearman rho\u2009=\u20090.44; <jats:italic>p<\/jats:italic>\u2009=\u20090.002; <jats:italic>n<\/jats:italic>\u2009=\u200946).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>sTREM2 in CSF correlates with aging in controls, and with the neurodegenerative markers CSF T-tau\/P-tau among controls who are negative for AD CSF core biomarkers A\u03b242, T-tau or P-tau.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-016-0182-1","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T13:01:18Z","timestamp":1461762078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Cerebrospinal fluid soluble TREM2 in aging and Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"8","author":[{"given":"Kristi","family":"Henjum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina S.","family":"Almdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"\u00c5rskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Minthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars N. G.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"182_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"182_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"182_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:257\u201362.","journal-title":"Alzheimers Dement"},{"key":"182_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"182_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nri3705","volume":"14","author":"MT Heneka","year":"2014","unstructured":"Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463\u201377.","journal-title":"Nat Rev Immunol"},{"key":"182_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1742-2094-11-120","volume":"11","author":"ER Zimmer","year":"2014","unstructured":"Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Tracking neuroinflammation in Alzheimer\u2019s disease: the role of positron emission tomography imaging. J Neuroinflammation. 2014;11:120.","journal-title":"J Neuroinflammation"},{"key":"182_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Biomark Med. 2012;6:455\u201376.","journal-title":"Biomark Med"},{"key":"182_CR8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:903\u201312.","journal-title":"Biol Psychiatry"},{"key":"182_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet. 2011;43:429\u201335.","journal-title":"Nat Genet"},{"key":"182_CR10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1094\u20139.","journal-title":"Nat Genet"},{"key":"182_CR11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45:1452\u20138.","journal-title":"Nat Genet"},{"key":"182_CR12","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1016\/j.neurobiolaging.2013.05.001","volume":"34","author":"P Forabosco","year":"2013","unstructured":"Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, et al. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging. 2013;34:2699\u2013714.","journal-title":"Neurobiol Aging"},{"key":"182_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bcp.2013.11.021","volume":"88","author":"SE Hickman","year":"2014","unstructured":"Hickman SE, El KJ. TREM2 and the neuroimmunology of Alzheimer\u2019s disease. Biochem Pharmacol. 2014;88:495\u20138.","journal-title":"Biochem Pharmacol"},{"key":"182_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"182_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368:107\u201316.","journal-title":"N Engl J Med"},{"key":"182_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2013.03.030","volume":"153","author":"B Zhang","year":"2013","unstructured":"Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer\u2019s disease. Cell. 2013;153:707\u201320.","journal-title":"Cell"},{"key":"182_CR17","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/glia.20710","volume":"56","author":"S Frank","year":"2008","unstructured":"Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438\u201347.","journal-title":"Glia"},{"key":"182_CR18","doi-asserted-by":"crossref","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra86.","DOI":"10.1126\/scitranslmed.3009093"},{"issue":"Pt 11","key":"182_CR19","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(Pt 11):3081\u201391.","journal-title":"Brain"},{"key":"182_CR20","doi-asserted-by":"publisher","first-page":"33027","DOI":"10.1074\/jbc.M113.517540","volume":"288","author":"P Wunderlich","year":"2013","unstructured":"Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem. 2013;288:33027\u201336.","journal-title":"J Biol Chem"},{"key":"182_CR21","volume-title":"Diagnostics and statistical manual of mental disorders","author":"G McKhann","year":"1987","unstructured":"McKhann G. Diagnostics and statistical manual of mental disorders. Arlington, VA: American Psychiatric Association; 1987."},{"key":"182_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"182_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56:248\u201353.","journal-title":"Clin Chem"},{"key":"182_CR24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","volume":"47","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47:1776\u201381.","journal-title":"Clin Chem"},{"key":"182_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaneurol.2013.579","volume":"70","author":"RJ Guerreiro","year":"2013","unstructured":"Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78\u201384.","journal-title":"JAMA Neurol"},{"key":"182_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231\u201345.","journal-title":"Mol Chem Neuropathol"},{"key":"182_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van KE, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49\u201352.","journal-title":"Neurosci Lett"},{"key":"182_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/13506120009146438","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele H, Van KE, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245\u201358.","journal-title":"Amyloid"},{"key":"182_CR29","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/nn.3554","volume":"16","author":"SE Hickman","year":"2013","unstructured":"Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896\u2013905.","journal-title":"Nat Neurosci"},{"key":"182_CR30","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","volume":"23","author":"SC Jin","year":"2014","unstructured":"Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, et al. Coding variants in TREM2 increase risk for Alzheimer\u2019s disease. Hum Mol Genet. 2014;23:5838\u201346.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"182_CR31","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1084\/jem.194.8.1111","volume":"194","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, Hernandez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194(8):1111\u201322.","journal-title":"J Exp Med"},{"key":"182_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1084\/jem.20141732","volume":"212","author":"K Wu","year":"2015","unstructured":"Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC, et al. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med. 2015;212:681\u201397.","journal-title":"J Exp Med"},{"key":"182_CR33","doi-asserted-by":"publisher","first-page":"e7134","DOI":"10.1371\/journal.pone.0007134","volume":"4","author":"J Morales-Corraliza","year":"2009","unstructured":"Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, et al. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. PLoS One. 2009;4:e7134.","journal-title":"PLoS One"},{"key":"182_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0197-4580(93)90100-P","volume":"14","author":"NR Nichols","year":"1993","unstructured":"Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993;14:421\u20139.","journal-title":"Neurobiol Aging"},{"key":"182_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bpa.12190","volume":"25","author":"LF Lue","year":"2015","unstructured":"Lue LF, Schmitz CT, Sorrano G, Sue LI, Beach TG, Walker DG. TREM2 protein expression changes correlate with Alzheimer\u2019s disease neurodegenerative pathologies in postmortem temporal cortices. Brain Pathol. 2015;25:469\u201380.","journal-title":"Brain Pathol"},{"key":"182_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.neurobiolaging.2014.09.003","volume":"36","author":"H Martiskainen","year":"2015","unstructured":"Martiskainen H, Viswanathan J, Nykanen NP, Kurki M, Helisalmi S, Natunen T, et al. Transcriptomics and mechanistic elucidation of Alzheimer\u2019s disease risk genes in the brain and in vitro models. Neurobiol Aging. 2015;36:1221\u20138.","journal-title":"Neurobiol Aging"},{"key":"182_CR37","doi-asserted-by":"crossref","unstructured":"Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer\u2019s disease. Brain. 2016;139:922-36.","DOI":"10.1093\/brain\/awv404"},{"key":"182_CR38","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1523\/JNEUROSCI.2620-14.2015","volume":"35","author":"M Kawabori","year":"2015","unstructured":"Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci. 2015;35:3384\u201396.","journal-title":"J Neurosci"},{"key":"182_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1083\/jcb.200808080","volume":"184","author":"EN N\u2019Diaye","year":"2009","unstructured":"N\u2019Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol. 2009;184:215\u201323.","journal-title":"J Cell Biol"},{"key":"182_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1471-4159.2009.06042.x","volume":"109","author":"CL Hsieh","year":"2009","unstructured":"Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144\u201356.","journal-title":"J Neurochem"},{"key":"182_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1084\/jem.20142322","volume":"212","author":"TR Jay","year":"2015","unstructured":"Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer\u2019s disease mouse models. J Exp Med. 2015;212:287\u201395.","journal-title":"J Exp Med"},{"key":"182_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1750-1326-9-20","volume":"9","author":"JD Ulrich","year":"2014","unstructured":"Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.","journal-title":"Mol Neurodegener"},{"key":"182_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"key":"182_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228\u201334.","journal-title":"Lancet Neurol"},{"key":"182_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122\u201331.","journal-title":"Ann Neurol"},{"key":"182_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jalz.2011.10.003","volume":"8","author":"D Paternico","year":"2012","unstructured":"Paternico D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, et al. Cerebrospinal fluid markers for Alzheimer\u2019s disease in a cognitively healthy cohort of young and old adults. Alzheimers Dement. 2012;8:520\u20137.","journal-title":"Alzheimers Dement"},{"key":"182_CR47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755\u201366.","journal-title":"Acta Neuropathol"},{"key":"182_CR48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1515\/CCLM.2004.071","volume":"42","author":"PR Burkhard","year":"2004","unstructured":"Burkhard PR, Fournier R, Mermillod B, Krause KH, Bouras C, Irminger I. Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations. Clin Chem Lab Med. 2004;42:396\u2013407.","journal-title":"Clin Chem Lab Med"},{"key":"182_CR49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-2001-3306","volume":"3","author":"M Shoji","year":"2001","unstructured":"Shoji M, Kanai M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. J Alzheimers Dis. 2001;3:313\u201321.","journal-title":"J Alzheimers Dis"},{"key":"182_CR50","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease. Science. 2010;330:1774.","journal-title":"Science"},{"key":"182_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-011-0801-7","volume":"121","author":"CA Hawkes","year":"2011","unstructured":"Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431\u201343.","journal-title":"Acta Neuropathol"},{"key":"182_CR52","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","volume":"73","author":"JT Jarrett","year":"1993","unstructured":"Jarrett JT, Lansbury Jr PT. Seeding \u2018one-dimensional crystallization\u2019 of amyloid: a pathogenic mechanism in Alzheimer\u2019s disease and scrapie? Cell. 1993;73:1055\u20138.","journal-title":"Cell"},{"key":"182_CR53","doi-asserted-by":"publisher","first-page":"895","DOI":"10.15252\/emmm.201505026","volume":"7","author":"LF Maia","year":"2015","unstructured":"Maia LF, Kaeser SA, Reichwald J, Lambert M, Obermuller U, Schelle J, et al. Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models. EMBO Mol Med. 2015;7:895\u2013903.","journal-title":"EMBO Mol Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-016-0182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-016-0182-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-016-0182-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-016-0182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T04:30:35Z","timestamp":1643603435000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-016-0182-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1186\/s13195-016-0182-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]},"assertion":[{"value":"9 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}